These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 28760302)

  • 1. Developmental Therapeutics in Myeloproliferative Neoplasms.
    Bose P; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S43-S52. PubMed ID: 28760302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK2 inhibitors for myeloproliferative neoplasms: what is next?
    Bose P; Verstovsek S
    Blood; 2017 Jul; 130(2):115-125. PubMed ID: 28500170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
    Griesshammer M; Sadjadian P
    Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapeutics in myeloproliferative neoplasms.
    Venugopal S; Mascarenhas J
    J Hematol Oncol; 2020 Dec; 13(1):162. PubMed ID: 33267911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management.
    Bose P; Verstovsek S
    J Natl Compr Canc Netw; 2016 Dec; 14(12):1613-1624. PubMed ID: 27956543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.
    Bose P; Verstovsek S
    Expert Opin Investig Drugs; 2016 Dec; 25(12):1393-1403. PubMed ID: 27756180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
    Berdeja J; Palandri F; Baer MR; Quick D; Kiladjian JJ; Martinelli G; Verma A; Hamid O; Walgren R; Pitou C; Li PL; Gerds AT
    Leuk Res; 2018 Aug; 71():82-88. PubMed ID: 30025280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).
    Mascarenhas J; Marcellino BK; Lu M; Kremyanskaya M; Fabris F; Sandy L; Mehrotra M; Houldsworth J; Najfeld V; El Jamal S; Petersen B; Moshier E; Hoffman R
    Leuk Res; 2020 Jan; 88():106272. PubMed ID: 31778911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1 study of the Janus kinase 2 (JAK2)
    Verstovsek S; Mesa RA; Salama ME; Li L; Pitou C; Nunes FP; Price GL; Giles JL; D'Souza DN; Walgren RA; Prchal JT
    Leuk Res; 2017 Oct; 61():89-95. PubMed ID: 28934680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging treatments for classical myeloproliferative neoplasms.
    Vannucchi AM; Harrison CN
    Blood; 2017 Feb; 129(6):693-703. PubMed ID: 28028027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
    Bryan JC; Verstovsek S
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting myeloproliferative neoplasms with JAK inhibitors.
    Pardanani A; Tefferi A
    Curr Opin Hematol; 2011 Mar; 18(2):105-10. PubMed ID: 21245760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN).
    Isfort S; von Bubnoff N; Al-Ali HK; Becker H; Götze T; le Coutre P; Griesshammer M; Moskwa C; Wohn L; Riedel J; Palandri F; Manz K; Hochhaus A; Döhner K; Heidel FH
    Ann Hematol; 2024 Aug; 103(8):2775-2785. PubMed ID: 38967662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Novel therapeutics in myeloproliferative neoplasms: beyond JAK inhibitors].
    Edahiro Y
    Rinsho Ketsueki; 2023; 64(9):970-980. PubMed ID: 37793873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature.
    Hunter AM; Bose P
    Expert Opin Pharmacother; 2024 Jul; 25(10):1391-1404. PubMed ID: 39067001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.
    Patel AB; Vellore NA; Deininger MW
    Clin Cancer Res; 2016 Mar; 22(5):1037-47. PubMed ID: 26933174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden.
    Mesa RA; Passamonti F
    Am Soc Clin Oncol Educ Book; 2016; 35():e324-35. PubMed ID: 27249739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Concepts of Treatment for Patients with Myelofibrosis.
    Bose P; Alfayez M; Verstovsek S
    Curr Treat Options Oncol; 2019 Jan; 20(1):5. PubMed ID: 30675650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.
    Loscocco GG; Vannucchi AM
    Int J Hematol; 2022 May; 115(5):626-644. PubMed ID: 35352288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.